[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oric Pharmaceuticals Inc (ORIC)

Oric Pharmaceuticals Inc (ORIC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It?

Oric Pharmaceuticals reports earnings on May 4, 2026, with analysts expecting the clinical-stage oncology company to post a loss of $0.31 per share. The central question is whether ORIC can continue its recent trend of beating estimates while demonstrating progress in its pipeline of precision oncology therapies. With the stock trading below all major moving averages and Wall Street maintaining overwhelmingly bullish price targets, this report will test whether operational momentum can reignite investor confidence.

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, with a pipeline targeting genetically defined cancers through novel mechanisms. The company's lead...

Fundamentals

See More
  • Market Capitalization, $K 1,011,371
  • Shares Outstanding, K 103,518
  • Annual Sales, $ 0 K
  • Annual Income, $ -129,470 K
  • EBIT $ -143 M
  • EBITDA $ -144 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.53

Options Overview Details

View History
  • Implied Volatility 196.94% (-0.81%)
  • Historical Volatility 170.90%
  • IV Percentile 68%
  • IV Rank 34.57%
  • IV High 436.15% on 02/05/26
  • IV Low 70.57% on 08/27/25
  • Expected Move (DTE 11) 2.13 (21.38%)
  • Put/Call Vol Ratio 50.00
  • Today's Volume 51
  • Volume Avg (30-Day) 339
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 9,935
  • Open Int (30-Day) 8,311
  • Expected Range 7.82 to 12.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 5
  • High Estimate $-0.28
  • Low Estimate $-0.35
  • Prior Year $-0.42
  • Growth Rate Est. (year over year) +26.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.68 +13.17%
on 04/07/26
11.16 -12.01%
on 04/20/26
+0.93 (+10.46%)
since 04/02/26
3-Month
7.23 +35.82%
on 04/02/26
14.25 -31.09%
on 02/25/26
-0.79 (-7.45%)
since 02/04/26
52-Week
4.52 +117.26%
on 05/07/25
14.93 -34.23%
on 10/07/25
+4.15 (+73.19%)
since 05/02/25

Most Recent Stories

More News
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It?

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 9.90 (+1.33%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It?

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 9.90 (+1.33%)
Oric's Rinzimetostat Data Suggests Pfizer Already Won the Prostate Cancer Race—Or Did It?

Barchart Research What to Expect from ORIC Earnings ORIC Generated May 1, 2026 Current Price $9.77 EPS Estimate $$-0.31 Consensus Rating Strong Buy Average Move 5.06% Oric's Rinzimetostat Data Suggests...

ORIC : 9.90 (+1.33%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms...

ORIC : 9.90 (+1.33%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

NEW YORK , April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 9.90 (+1.33%)
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 9.90 (+1.33%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. ("Oric" or the "Company") (NASDAQ: ORIC).  Such investors are...

ORIC : 9.90 (+1.33%)
ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ORIC Pharmaceuticals, Inc. (“Oric” or “the Company”)...

ORIC : 9.90 (+1.33%)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...

ORIC : 9.90 (+1.33%)
Stocks Settle Higher on Hopes for Conclusion to Iran War

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed up +0.72%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.18%. June E-mini...

ALK : 38.02 (-1.37%)
MPC : 250.60 (+1.81%)
SNDK : 1,242.90 (+4.71%)
HL : 17.92 (-0.78%)
CDE : 17.63 (-0.11%)
LITE : 960.57 (+1.12%)
OXY : 59.43 (+1.23%)
NCNO : 18.20 (+0.39%)
GLW : 160.01 (+1.11%)
FANG : 211.12 (+1.67%)
STX : 736.06 (+1.26%)
WDC : 435.05 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ORIC Pharmaceuticals Inc. is a clinical stage oncology company. It is focused on developing treatments which address mechanisms of therapeutic resistance. The company's product candidate consists of ORIC-101 and ORIC-533 which are in clinical stage. ORIC Pharmaceuticals Inc. is based in San Francisco,...

See More

Key Turning Points

3rd Resistance Point 10.52
2nd Resistance Point 10.32
1st Resistance Point 10.05
Last Price 9.90
1st Support Level 9.57
2nd Support Level 9.37
3rd Support Level 9.10

See More

52-Week High 14.93
Fibonacci 61.8% 10.95
Last Price 9.90
Fibonacci 50% 9.73
Fibonacci 38.2% 8.50
52-Week Low 4.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.